Tomer Kariv - Jun 15, 2022 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Role
Director
Signature
/s/ Sumit Aggarwal, Attorney-in-Fact for Tomer Kariv
Stock symbol
ELOX
Transactions as of
Jun 15, 2022
Transactions value $
$0
Form type
4
Date filed
6/17/2022, 08:24 AM
Previous filing
Jun 3, 2022
Next filing
Nov 30, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ELOX Stock Options (Right to Buy) Award $0 +20K $0.00 20K Jun 15, 2022 Common Stock 20K $0.26 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests as to 50% of the underlying shares on June 15, 2023 and the remainder in twelve (12) equal monthly installments thereafter.
F2 The Reporting Person will assign the economic interests of this grant to the Pontifax funds, where he serves as a director of the General Partner.